A perspective on partially hydrolyzed protein infant formula in nonexclusively breastfed infants
- Author:
Yvan VANDENPLAS
1
;
Zakiudin MUNASIR
;
Badriul HEGAR
;
Dewi KUMARAWATI
;
Ahmad SURYAWAN
;
Muzal KADIM
;
Julistio Tb DJAIS
;
Ray Wagiu BASROWI
;
Deni KRISNAMURTI
Author Information
- Publication Type:Review
- Keywords: Partial hydrolysate; Cow's milk protein allergy; Breastfeeding; Formula feeding; Hydrolysate; Infant feeding
- MeSH: Breast Feeding; Critical Period (Psychology); Epidemiologic Studies; Food Hypersensitivity; Humans; Hypersensitivity; Infant Formula; Infant; Milk; Milk Hypersensitivity; Whey; World Health Organization
- From:Korean Journal of Pediatrics 2019;62(5):149-154
- CountryRepublic of Korea
- Language:English
- Abstract: The World Health Organization recommends that infants should be exclusively breastfed for the first 6 months of life to provide optimal nutrition in this critical period of life. After this, infants should receive nutritionally adequate and safe complementary foods while breastfeeding continues for up to 2 years of age or beyond. For nonbreastfed infants, infant formula is an available option to provide the nutrition needed. Infant formula is usually prepared from industrially modified cow's milk and processed to adjust for the nutritional needs of infants. However, cow's milk is one of the most common causes of food allergy, affecting 2%–5% of all formula-fed infants during their first year of life. One strategy to prevent cow's milk allergy in nonbreastfed infants is the use of partially hydrolyzed formula (pHF) in high-risk infants, which are infants born in families with atopic disease. However, based on an epidemiological study, approximately half of the infants who develop allergy are not part of the at-risk group. This is because the non-at-risk group is significantly larger than the at-risk group and the non-at-risk infants have approximately 15% risk of developing allergies. This study aimed to evaluate the effects of partially hydrolyzed whey formula (pHF-W) in nonbreastfed infants and determine whether pHF-W can prevent atopic disease in high-risk infants and can be used as routine starter formula regardless of the allergy risk status.
